CARMAN (#1462) Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B) (Aktiv)
VIRAL - EMCL elderly III trial Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms (Aktiv)
Zweitlinie oder später
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
LOXO-BTK-20019/ BRUIN-MCL-321(#1349) A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321) (Aktiv)
Lymrit-37-01 A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. (Aktiv)